Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that it will be attending the 19th annual BIO-Europe Spring taking place March 17-19, 2025 in Milan, Italy. The event is expected to bring together over 3,700 executives from biotech, pharma and finance companies to engage in 20,000+ one-to-one meetings.
"BIO-Europe Spring® is a key annual event in Europe for pursuing partnering discussions. We look forward to building on a positive momentum to continuing discussions around our clinical-stage HDAC inhibitor portfolio, CS1 and CS014, both with disease-modifying potential. Over the past year, we have made significant progress with CS1 reporting positive top-line data from our Phase IIa trial in rare disease PAH and CS014, targeting rare disease IPF, advancing on plan towards Phase I completion and results by mid-2025," said Sten R. Sörensen, CEO of Cereno Scientific. "The strong interest we receive when engaging with industry stakeholders reinforces the market's enthusiasm for innovative treatment approaches in rare cardiovascular and pulmonary diseases."
Sten R. Sörensen, CEO, and Rahul Agrawal, CMO & Head of R&D, will attend. To schedule a meeting with Cereno Scientific register at https://informaconnect.com/bioeurope-spring/.
BIO-Europe Spring® is the place to meet the world under one roof and discover the latest innovations which will advance the medicines of tomorrow. The organizers EBD Group is committed to providing a forum for the global biopharma community to come together. This year's event features two days of digital partnering in the week following the in-person event.
For further information, please contact:
Tove Bergenholt, Head of IR & Communications
Email: tove.bergenholt@cerenoscientific.com
Phone: +46 73- 236 62 46
Sten R. Sörensen, CEO
Email: sten.sorensen@cerenoscientific.com
Phone: +46 73-374 03 74
About BIO-EUROPE SPRING®
BIO-Europe Spring's goal is to connect Europe's top innovation centers with the global life science industry Its international reach makes it a one of a kind offering and gateway to the global life science community. The event will cater to the needs of the entire value chain, start-up and innovator educational programs, industry trends and outlooks from KOLs, company pitches, professional partnering meetings as well as various networking opportunities are part of the ROI proven feature set. BIO-Europe Spring is produced by EBD Group, the leading partnering firm for the global biotechnology industry, with the support of the Biotechnology Innovation Organization (BIO).
About Cereno Scientific AB
Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full.
Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1's safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 was safe, well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. HDACi CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 employs a multi-modal mechanism of action as an epigenetic modulator, targeting key unmet needs in patients with rare disease Idiopathic Pulmonary Fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension.
The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.